Skip to main content
All lobbying filings

FEROX STRATEGIES

FEROX STRATEGIES filed a Q3 report for ATRIUM THERAPEUTICS on October 19, 2026, reporting $80,000 in lobbying income.

Lobbying for ATRIUM THERAPEUTICS · Biotechnology company

All filings by FEROX STRATEGIES · Everything ATRIUM THERAPEUTICS has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$80,000
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Health Issues

General issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem